Remote Ischemic Conditioning: Feasible and Potentially Beneficial for Ischemic Stroke

David C. Hess; Rolf A. Blauenfeldt; Grethe Andersen

doi:10.1001/jama.2022.13365

Remote Ischemic Conditioning: Feasible and Potentially Beneficial for Ischemic Stroke

David C. Hess
, Rolf A. Blauenfeldt
, Grethe Andersen

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	622-624
Number of pages	3
Journal	JAMA
Volume	328
Issue number	7
DOIs	https://doi.org/10.1001/jama.2022.13365
State	Published - Aug 16 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2022.13365

Cite this

@article{6d978148b74349c899ff4f34432d3ba2,

title = "Remote Ischemic Conditioning: Feasible and Potentially Beneficial for Ischemic Stroke",

author = "Hess, \{David C.\} and Blauenfeldt, \{Rolf A.\} and Grethe Andersen",

note = "Funding Information: having a patent with Augusta University and Athersys Inc for stem cells in neurologic diseases and being on the scientific advisory board for Athersys, Inc. Dr Blauenfeldt reported receiving personal fees from Bayer and Novo Nordisk. The authors reported receiving support from the National Institutes of Health (R01 NS099455, Dr Hess; 1UO1NS113356, Dr Hess; R01NS112511, Drs Hess, Blauenfeldt, and Andersen), Vilhelm Petersens Mindelegat, TrygFonden, and the Novo Nordisk Foundation (Dr Andersen).",

year = "2022",

month = aug,

day = "16",

doi = "10.1001/jama.2022.13365",

language = "English (US)",

volume = "328",

pages = "622--624",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "7",

}

TY - JOUR

T1 - Remote Ischemic Conditioning

T2 - Feasible and Potentially Beneficial for Ischemic Stroke

AU - Hess, David C.

AU - Blauenfeldt, Rolf A.

AU - Andersen, Grethe

N1 - Funding Information: having a patent with Augusta University and Athersys Inc for stem cells in neurologic diseases and being on the scientific advisory board for Athersys, Inc. Dr Blauenfeldt reported receiving personal fees from Bayer and Novo Nordisk. The authors reported receiving support from the National Institutes of Health (R01 NS099455, Dr Hess; 1UO1NS113356, Dr Hess; R01NS112511, Drs Hess, Blauenfeldt, and Andersen), Vilhelm Petersens Mindelegat, TrygFonden, and the Novo Nordisk Foundation (Dr Andersen).

PY - 2022/8/16

Y1 - 2022/8/16

UR - https://www.scopus.com/pages/publications/85136908571

UR - https://www.scopus.com/pages/publications/85136908571#tab=citedBy

U2 - 10.1001/jama.2022.13365

DO - 10.1001/jama.2022.13365

M3 - Comment/debate

C2 - 35972503

AN - SCOPUS:85136908571

SN - 0098-7484

VL - 328

SP - 622

EP - 624

JO - JAMA

JF - JAMA

IS - 7

ER -

Remote Ischemic Conditioning: Feasible and Potentially Beneficial for Ischemic Stroke

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this